![](https://ml.globenewswire.com/media/55a392f2-81c7-4e85-a884-d9be38871c5c/small/fibrogen-us-primary-logo-rgb-m01-jpg.jpg)
FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate ...
Pamrevlumab arm of the Precision PromiseSM study in metastatic pancreatic cancer, sponsored and conducted by the Pancreatic Cancer Action Network (PanCAN), did not meet the primary endpoint of overall survival as determined by the protocol pre-specified …